SCHEMBL1496987

SCHEMBL1496987

CCCCCCNC(=O)N(CCN(C)C)Cc1ccc(C(=O)Nc2cscc2N)nc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.36
THRB P10828 1/20 0.36
PDCD1 Q15116 4/20 0.36
CD274 Q9NZQ7 4/20 0.36
KDM4E B2RXH2 2/20 0.36
ROCK1 Q13464 1/20 0.35
HDAC1 Q13547 5/20 0.35
HDAC3 O15379 3/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC6 Q9UBN7 2/20 0.34
ALOX15 P16050 2/20 0.34
ALDH1A1 P00352 2/20 0.34
NFKB1 P19838 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8004725 0.93 PDCD1 (0.37) PDCD1CD274ROCK1HDAC1HDAC3
SCHEMBL1496903 0.89 PDCD1 (0.38) PDCD1CD274ROCK1HDAC1HDAC3
SCHEMBL1496888 0.89 ROCK1 (0.40) PDCD1CD274ROCK1HDAC1HDAC3
SCHEMBL4231180 0.89 HDAC3 (0.46) PDCD1CD274HDAC1HDAC3HDAC2
SCHEMBL1483172 0.86 HIF1A (0.42) PDCD1CD274ROCK1HDAC1HDAC3
SCHEMBL7989983 0.86 HDAC1 (0.36) THRATHRBPDCD1CD274KDM4E
SCHEMBL1496953 0.85 PDCD1 (0.35) PDCD1CD274ROCK1HDAC1HDAC3
SCHEMBL8004129 0.85 ROCK2 (0.40) PDCD1CD274ROCK1HDAC1HDAC3
SCHEMBL1497176 0.85 PDCD1 (0.39) PDCD1CD274ROCK1HDAC1HDAC3
SCHEMBL1497080 0.84 USP2 (0.44) THRBKDM4EHDAC1HDAC6ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288380-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-10-16 US disclosed
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
US-8198271-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-06-12 US disclosed
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-31 US disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
WO-2009142321-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE 参天製薬株式会社 (JP) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE CBR1, NAT1, PRMT1 THRA 613/4885THRB 475/4885PDCD1 4160/4885
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE HNMT, HRH4, CHRM1 THRA 854/4885THRB 788/4885PDCD1 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.